VX-147 for APOL1-Mediated Proteinuric Kidney Disease
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
- Age
- 10 – 65
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 466 (estimated)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
This trial is looking for adults and children with a specific type of kidney disease caused by genetics. Participants will receive the drug VX-147 to assess its effectiveness and safety.
You may be able to join if
- I have the APOL1 genotype G1/G1, G2/G2, or G1/G2
- I have been diagnosed with proteinuric kidney disease
You may not be able to join if
- I have had a solid organ or bone marrow transplant
- My blood pressure is not under control
- I have a history of diabetes
- I have a known underlying cause of kidney disease
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Loading trial locations…